ES2231007B2 - CREAM FOR THE TREATMENT OF PSORIASIS. - Google Patents
CREAM FOR THE TREATMENT OF PSORIASIS.Info
- Publication number
- ES2231007B2 ES2231007B2 ES200302375A ES200302375A ES2231007B2 ES 2231007 B2 ES2231007 B2 ES 2231007B2 ES 200302375 A ES200302375 A ES 200302375A ES 200302375 A ES200302375 A ES 200302375A ES 2231007 B2 ES2231007 B2 ES 2231007B2
- Authority
- ES
- Spain
- Prior art keywords
- cream
- psoriasis
- until
- propylene glycol
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 201000004681 Psoriasis Diseases 0.000 title claims abstract description 13
- 238000011282 treatment Methods 0.000 title claims abstract description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000006071 cream Substances 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000013162 Cocos nucifera Nutrition 0.000 claims abstract description 5
- 244000060011 Cocos nucifera Species 0.000 claims abstract description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000002253 acid Substances 0.000 claims abstract description 5
- 239000004202 carbamide Substances 0.000 claims abstract description 5
- 239000012153 distilled water Substances 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims abstract description 4
- 239000002674 ointment Substances 0.000 claims abstract description 4
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229960004889 salicylic acid Drugs 0.000 claims abstract description 4
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims abstract description 4
- 229960005294 triamcinolone Drugs 0.000 claims abstract description 4
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 claims abstract description 3
- 239000004251 Ammonium lactate Substances 0.000 claims abstract description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims abstract description 3
- 229940059265 ammonium lactate Drugs 0.000 claims abstract description 3
- 235000019286 ammonium lactate Nutrition 0.000 claims abstract description 3
- RZOBLYBZQXQGFY-HSHFZTNMSA-N azanium;(2r)-2-hydroxypropanoate Chemical compound [NH4+].C[C@@H](O)C([O-])=O RZOBLYBZQXQGFY-HSHFZTNMSA-N 0.000 claims abstract description 3
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000008311 hydrophilic ointment Substances 0.000 claims abstract description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims abstract description 3
- 235000019271 petrolatum Nutrition 0.000 claims abstract description 3
- 239000011521 glass Substances 0.000 claims description 4
- 238000000265 homogenisation Methods 0.000 claims description 4
- 239000004570 mortar (masonry) Substances 0.000 claims description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 2
- 229930182566 Gentamicin Natural products 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- RZOBLYBZQXQGFY-UHFFFAOYSA-N ammonium lactate Chemical compound [NH4+].CC(O)C([O-])=O RZOBLYBZQXQGFY-UHFFFAOYSA-N 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 229960002518 gentamicin Drugs 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 229940099259 vaseline Drugs 0.000 claims description 2
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 abstract description 2
- 239000004264 Petrolatum Substances 0.000 abstract 1
- 229940066842 petrolatum Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001126 phototherapy Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 2
- 229960002882 calcipotriol Drugs 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 description 2
- 229960002199 etretinate Drugs 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 208000007180 Sunstroke Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 description 1
- 230000002682 anti-psoriatic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000030499 combat disease Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- -1 ditranol Chemical compound 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 229940043810 zinc pyrithione Drugs 0.000 description 1
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Crema para el tratamiento de la psoriasis, comprende: ungüento hidrófilo, urea, ácido salicílico, tardoak, gentamicina sulfato acetónido triamcinolona, lactato amónico, dietanolamina de ácidos de coco (cocamida), estando dicho ungüento hidófilo formado por: cera lanette-N, vaselina filante, lauril sulfato sódico, propilenglicol, agua destilada, nipagin cs. Se reivindica también el método para la elaboración de la crema.Cream for the treatment of psoriasis, comprises: hydrophilic ointment, urea, salicylic acid, tardoak, gentamicin sulfate acetonide triamcinolone, ammonium lactate, coconut acid diethanolamine (cocamide), said ointment being hydrophilic formed by: wax lanette-N, petrolatum filament, sodium lauryl sulfate, propylene glycol, distilled water, nipagin cs. The method for the elaboration of the cream.
De aplicación en la fabricación de una crema contra la psoriasis.Of application in the manufacture of a cream against psoriasis
Description
Crema para el tratamiento de la psoriasis.Cream for the treatment of psoriasis.
El sector de la técnica de esta invención es el de las cremas y formulas que tienen corno finalidad la aplicación dermatológica para la eliminación de los síntomas y manifestaciones de la citada enfermedad.The technical sector of this invention is the of the creams and formulas that have as purpose the application dermatological for the elimination of symptoms and manifestations of the said disease.
Indicación del Estado de la Técnica anterior. La
psoriasis se considera una enfermedad que por sus características
es más molesta que grave, puesto que sólo se consideran serias las
variedades pustulosa y eritrodérmica de la enfer-
medad.Indication of the prior art. Psoriasis is considered a disease that, due to its characteristics, is more annoying than serious, since only the pustular and erythrodermic varieties of the patient are considered serious
piss
Esta enfermedad está relacionada con la respuesta inmune y 1 la inflamación. Las células nuevas de la piel normal tardan aproximadamente 1 mes en emigrar desde las capas más profundas de la piel hasta la superficie; en la psoriasis, este proceso sólo lleva unos días, de forma que hay un recambio constante de células, las células muertas no pueden descamarse lentamente y persisten formando grandes escamas.This disease is related to the response Immune and 1 inflammation. New cells of normal skin it takes about 1 month to migrate from the most layers deep from the skin to the surface; in psoriasis, this process only takes a few days, so that there is a constant replacement of cells, dead cells cannot slowly peel and they persist forming large scales.
Se manifiesta a través de unas placas que aparecen en ciertas partes del cuerpo las cuales pueden extenderse, hacerse mayores, y reducirse según circunstancias no claramente conocidas, y entre las que influyen las toxinas, y por ello es relevante el estado de nerviosismo del paciente, las características de su ingesta alimenticia, el consumo de alcohol, y otros factores como la temperatura ambiente, insolación e incluso de la calidad del aire respirado o el buen funcionamiento de las vías aéreas del individuo. También puede influir la medicación para curar otras enfermedades. Se tiene por enfermedad familiar genética de tipo hereditario y parece ser que el sistema inmunológico de cada persona es determinante para su aparición.It manifests through plates that appear on certain parts of the body which can spread, grow older, and reduce according to circumstances not clearly known, and among which the toxins influence, and therefore it is relevant state of nervousness of the patient, the characteristics of your food intake, alcohol consumption, and other factors such as room temperature, sunstroke and even of the quality of the air breathed or the proper functioning of the Airways of the individual. Medication can also influence to Cure other diseases. You have genetic family disease of hereditary type and it seems that the immune system of Each person is decisive for its appearance.
La psoriasis se ha tratado fundamentalmente
mediante dos sistemas. Uno de ellos, mediante la ingestión de
fármacos administrados por vía oral (etretinato, metotrexato,
ciclosporina), son fármacos agresivos con importantes efectos
secundarios por lo que deben ser utilizados solo en psoriasis muy
importantes y bajo estricto control
médico.Psoriasis has been treated primarily by two systems. One of them, by ingesting orally administered drugs (etretinate, methotrexate, cyclosporine), are aggressive drugs with significant side effects and should therefore be used only in very important psoriasis and under strict control.
doctor.
Otro es el tratamiento a base de cremas, pomadas y lociones capilares con distintos principios activos (calcipotriol, corticoides, ditranol, ácido salicílico). Es la forma de tratamiento más ampliamente utilizada e indicada siempre que la afectación sea menor de 35% de la superficie corporal.Another is the treatment based on creams, ointments and hair lotions with different active ingredients (calcipotriol, corticosteroids, ditranol, salicylic acid). Is the most widely used and indicated treatment form that the affectation is less than 35% of the body surface.
Un tercer sistema complementario a alguno de los anteriores es la fototerapia. Suele tener efectos secundarios a largo plazo.A third system complementary to any of the Previous is phototherapy. It usually has side effects to long term.
El tratamiento habitual aplicado por los médicos
incluye opciones de tratamientos anti-psoriásicos,
incluyendo agentes locales (esteroides, alquitrán, antralina y
calcipotriol), fototerapia (UVB, PUVA), y tratamientos sistémicos
(metotrexato, ciclosporina y etretinato). Frecuentemente es
necesaria una combinación de modalidades de tratamiento para lograr
el éxito clínico. Desafortunadamente, las modalidades de
fototerapia pueden ser laboriosas e incómodas. Los tratamientos
sistémicos tienen importantes efectos adversos. También es
utilizada una preparación conteniendo piritionato de zinc (0.25%)
en un vehículo con miristato de isopropilo para tratar ciertos casos
de
psoriasis.The usual treatment applied by doctors includes options for anti-psoriatic treatments, including local agents (steroids, tar, anthraline and calcipotriol), phototherapy (UVB, PUVA), and systemic treatments (methotrexate, cyclosporine and etretinate). A combination of treatment modalities is often necessary to achieve clinical success. Unfortunately, phototherapy modalities can be laborious and uncomfortable. Systemic treatments have important adverse effects. A preparation containing zinc pyrithione (0.25%) is also used in a vehicle with isopropyl myristate to treat certain cases of
psoriasis.
La presente invención tiene por objeto una crema para el tratamiento de la psoriasis que está basada en un conjunto de principios activos dispuestos en un excipiente y que en conjunto alcanzan a producir efectos beneficiosos para el paciente, hasta la total desaparición de los síntomas de la enfermedad.The present invention aims at a cream for the treatment of psoriasis that is based on a set of active ingredients arranged in an excipient and which together they reach to produce beneficial effects for the patient, until the Total disappearance of disease symptoms.
Consiste dicha formula en:This formula consists of:
\newpage\ newpage
El ungüento hidrófilo está compuesto por:The hydrophilic ointment is composed of:
Dichas cantidades, pueden sufrir pequeñas variaciones en función de necesidades concretas, basadas en la específica necesidad de combatir los síntomas de la enfermedad para ciertas variedades de la misma.These amounts may suffer small variations based on specific needs, based on the specific need to combat disease symptoms to Certain varieties of it.
Un modo de realización ha quedado claramente indicado.An embodiment has been clearly indicated.
La elaboración de dicha crema tiene lugar mediante un método para el que se precisa:The elaboration of said cream takes place through a method for which it is required:
- vasos de precipitados- beakers
- varilla- rod
- mortero - pistilo- mortar - pistil
- medios para someter a baño maría.- means to submit to a water bath.
1) En un vaso de precipitados (A) se disponen los componentes de la fase grasa, compuesta por:1) In a beaker (A) the Fat phase components, consisting of:
- cera lanette-n- wax lanette-n
- vaselina filante- petroleum jelly
- tardoak- tardoak
- dietanol amina de ácidos grasos de coco (cocamida)- coconut fatty acid dietanol amine (cocamida)
En otro vaso de precipitados (B) se disponen los componentes de la fase acuosa, compuesta por:In another beaker (B) the Water phase components, consisting of:
- lauril sulfato sódico- sodium lauryl sulfate
- propilenglicol- propylene glycol
- agua destilada- distilled water
- nipagin- nipagin
- ureaurea
Ambos vasos se llevan al baño maría hasta que el contenido de la fase grasa (vaso A) haya pasado a la forma líquida.Both glasses are taken to the water bath until the fat phase content (vessel A) has passed into the form liquid
2) Se retiran los vasos del baño maría, y en el vaso B -aún caliente- se incorpora la gentamicina hasta su disolución.2) The vessels are removed from the water bath, and in the glass B - still hot - the gentamicin is incorporated until its dissolution.
3) Posteriormente se vierte B sobre A y se remueve con varilla hasta su homogeneización y tome cuerpo.3) Subsequently B is poured over A and stir with rod until homogenization and take body.
4) Se añade el lactato amónico hasta su completa homogeneización.4) Ammonium lactate is added until complete homogenization
5) En un mortero se dispone el ácido salicílico y la triamcinolona. Se emulsiona con un poco de propilenglicol y se incorpora la mezcla anterior. Se remueve hasta homogeneizarla completamente.5) In a mortar the salicylic acid and Triamcinolone It is emulsified with a little propylene glycol and it is incorporate the previous mixture. Remove until homogenized completely.
6) Envasado en tarro protegido de la luz.6) Packaged in jar protected from light.
Es susceptible de aplicación industrial, en la fabricación de una crema contra la psoriasis.It is susceptible of industrial application, in the manufacture of a cream against psoriasis.
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200302375A ES2231007B2 (en) | 2003-10-13 | 2003-10-13 | CREAM FOR THE TREATMENT OF PSORIASIS. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200302375A ES2231007B2 (en) | 2003-10-13 | 2003-10-13 | CREAM FOR THE TREATMENT OF PSORIASIS. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2231007A1 ES2231007A1 (en) | 2005-05-01 |
| ES2231007B2 true ES2231007B2 (en) | 2006-09-16 |
Family
ID=34565986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES200302375A Expired - Fee Related ES2231007B2 (en) | 2003-10-13 | 2003-10-13 | CREAM FOR THE TREATMENT OF PSORIASIS. |
Country Status (1)
| Country | Link |
|---|---|
| ES (1) | ES2231007B2 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2258402B1 (en) * | 2005-02-09 | 2007-12-01 | Antonio Becerra Carnero | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PSORIASIS AND OTHER SKIN AFFECTIONS. |
| ES2288133B1 (en) * | 2006-06-12 | 2008-09-16 | Maria Cristina Fernandez Rodriguez | TOPICAL COMPOSITION FOR THE TREATMENT OF PSORIASIS. |
| ES2489615T3 (en) | 2007-12-11 | 2014-09-02 | Apoteknos Para La Piel, S.L. | Use of a compound derived from p-hydroxyphenyl propionic acid for the treatment of psoriasis |
| ES2377616B1 (en) * | 2010-09-01 | 2013-02-13 | M. Cristina Fernández Rodríguez | STABILIZING COMPOSITION FOR TOPICAL APPLICATION FORMULATIONS AND USING THE SAME. |
| CN121285366A (en) * | 2023-06-06 | 2026-01-06 | 特尔拉多瓦私人有限公司 | Psoriasis treatment |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4512978A (en) * | 1980-01-24 | 1985-04-23 | Inwood Louis R | Dermatological composition useful in the treatment of psoriasis |
| US4740372A (en) * | 1986-09-17 | 1988-04-26 | Ljubomir Boncic | Composition for treating psoriasis vulgaris and a method for its preparation |
| DE4119170A1 (en) * | 1991-06-11 | 1992-12-17 | Miltner Geb Herber Erika Dr | Synergistic compsn. for treating neuro-dermatitis - comprises triamcinolone acetonide, salicylic acid or its acetyl deriv., and coal tar extract |
| WO1994013354A1 (en) * | 1992-12-07 | 1994-06-23 | Creative Products Resource, Inc. | In-tandem applicator pads for therapeutic agents |
| ES2119726A1 (en) * | 1997-03-20 | 1998-10-01 | Reolid Manuel Sanchez | Composition of a product for application on the body. |
-
2003
- 2003-10-13 ES ES200302375A patent/ES2231007B2/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4512978A (en) * | 1980-01-24 | 1985-04-23 | Inwood Louis R | Dermatological composition useful in the treatment of psoriasis |
| US4740372A (en) * | 1986-09-17 | 1988-04-26 | Ljubomir Boncic | Composition for treating psoriasis vulgaris and a method for its preparation |
| DE4119170A1 (en) * | 1991-06-11 | 1992-12-17 | Miltner Geb Herber Erika Dr | Synergistic compsn. for treating neuro-dermatitis - comprises triamcinolone acetonide, salicylic acid or its acetyl deriv., and coal tar extract |
| WO1994013354A1 (en) * | 1992-12-07 | 1994-06-23 | Creative Products Resource, Inc. | In-tandem applicator pads for therapeutic agents |
| ES2119726A1 (en) * | 1997-03-20 | 1998-10-01 | Reolid Manuel Sanchez | Composition of a product for application on the body. |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2231007A1 (en) | 2005-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2278393T3 (en) | ANTIMICROBIAL TREATMENT OF VIRUS HERPES SIMPLEX AND OTHER INFECTIOUS DISEASES. | |
| ES2456502T3 (en) | Composition comprising PNC or GNP for an external skin preparation for the treatment of dermatitis | |
| ES2998817T3 (en) | Topical formulations comprising cannabidiol, method of preparing the composition and use thereof | |
| ES2611314T3 (en) | Compositions and procedures for using (R) -pramipexole | |
| JP5968865B2 (en) | Topical coenzyme Q10 formulation and treatment of pain, fatigue, and wounds | |
| ES2484315T3 (en) | Treatment of loss of sense of touch with saxitoxin derivatives | |
| US20100137357A1 (en) | Compositions and methods for hyperhidrosis | |
| US8822477B2 (en) | Use of osmolytes obtained from extremophilic bacteria for producing medicine for the external treatment of neurodermatitis | |
| CN102366437A (en) | Compound dexamethasone ointment and preparation method thereof | |
| KR102641917B1 (en) | Composition comprising fragmented DNA mixture and chitosan for preventing or treating of atopic dermatitis | |
| ES2231007B2 (en) | CREAM FOR THE TREATMENT OF PSORIASIS. | |
| ES2240987T3 (en) | THERAPEUTIC COMPOSITION FOR EXTERNAL USE CONTAINING ADRENAL CORTICOESTEROIDS FOR THE TREATMENT OF DERMATITIS. | |
| CN104107162B (en) | A kind of micro emulsion gels pharmaceutical composition and preparation method thereof | |
| TW201902474A (en) | Compounds for treating stroke and reducing nerve damage and uses thereof | |
| WO2016029328A1 (en) | Pharmaceutical composition for preventing, treating, and curing psoriasis including snail slime, chamomile, and honey | |
| CN107519236A (en) | A kind of topical agent for treating onychomycosis | |
| WO2016054757A1 (en) | Pharmaceutical composition for preventing, treating and curing rosacea, comprising snail slime, camomile and propolis | |
| CN108635253A (en) | A kind of infant's egg oil cosmetics | |
| ES2379474T3 (en) | Dermatological product for the treatment and / or skin care with neurodermitis | |
| ES2288133B1 (en) | TOPICAL COMPOSITION FOR THE TREATMENT OF PSORIASIS. | |
| CN101496833A (en) | Liquid external preparation for preparing total alkaloids in nux vomica | |
| EP4079303B1 (en) | Naphthylurea compound for treating corneal neovascular disease | |
| CN116585447A (en) | Cerebral apoplexy combined medicine and application thereof | |
| ES2274721B1 (en) | NEW THERAPEUTIC AGENT FOR THE TREATMENT OF A CONDITION ASSOCIATED WITH PERIPHERAL VASCULAR DISEASE. | |
| CN104490870A (en) | Compound topical cream and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EC2A | Search report published |
Date of ref document: 20050501 Kind code of ref document: A1 |
|
| FG2A | Definitive protection |
Ref document number: 2231007B2 Country of ref document: ES |
|
| FD2A | Announcement of lapse in spain |
Effective date: 20211118 |